Is it safe to perform a colonoscopy in a patient with active herpes zoster involving the buttocks and perianal area?

Colonoscopy Safety in Active Perianal/Buttock Herpes Zoster

Colonoscopy should be postponed in patients with active herpes zoster involving the buttocks and perianal area until the lesions have healed and the acute infection has resolved. This recommendation prioritizes patient safety, procedural complications, and infection control.

Primary Reasoning

Risk of Viral Dissemination and Complications

Active herpes zoster in the perianal region creates several significant concerns:

• Visceral motor complications: Herpes zoster can cause gastrointestinal visceral neuropathy, leading to colonic pseudo-obstruction (Ogilvie's syndrome) or intestinal pseudo-obstruction 1, 2, 3, 4. These complications occur when the virus affects the autonomic nervous system controlling bowel motility.

• Mechanical trauma risk: Colonoscopy involves instrumentation through the affected area, which could:

  • Traumatize active vesicular lesions
  • Potentially spread viral particles
  • Increase pain and patient discomfort significantly
  • Risk secondary bacterial infection of disrupted lesions

• Diagnostic confusion: If the patient develops abdominal distention or pseudo-obstruction during or after the procedure, it becomes difficult to distinguish between procedure-related complications and herpes zoster-induced visceral neuropathy 2, 3.

Infection Control Considerations

While the provided guidelines focus on COVID-19 protocols 5, 6, 5, the principles of infection control during endoscopy apply to active viral infections:

• Active viral shedding from perianal lesions poses contamination risks to endoscopy equipment and staff
• Standard endoscope reprocessing is effective, but the risk-benefit ratio shifts unfavorably when the procedure is non-urgent

Special Considerations for IBD Patients

If this patient has inflammatory bowel disease (which is a common indication for colonoscopy), additional factors apply:

• Immunosuppression increases herpes zoster risk: IBD patients on immunosuppressive therapy have higher rates of herpes zoster 7
• Documented case of VZV in hemorrhoids: A case report describes isolated VZV infection in hemorrhoids in an IBD patient on adalimumab 8, demonstrating that the virus can localize to anorectal tissues
• Vaccination guidance: The 2025 BSG guidelines recommend recombinant zoster vaccination for IBD patients on immunosuppressants 9, but advise avoiding live vaccines and procedures during active infections

Clinical Algorithm for Decision-Making

When to Postpone (Non-Urgent Indications):

• Routine surveillance colonoscopy
• Mucosal healing assessment
• Follow-up after biologic initiation
• Postoperative recurrence assessment

Action: Delay 2-4 weeks until vesicles have crusted over and acute pain has resolved

When to Proceed with Extreme Caution (Urgent/Emergency Indications):

Based on IBD emergency guidelines 5, 6, proceed only if:

• Acute severe colitis refractory to medical treatment
• Active GI bleeding not amenable to other interventions
• Suspected invasive colorectal cancer/high-grade dysplasia
• Acute obstruction requiring endoscopic intervention

Action:

1. Start antiviral therapy (acyclovir, valacyclovir, or famciclovir) immediately
2. Provide adequate analgesia
3. Use enhanced infection control precautions
4. Consider alternative imaging (CT/MRI) if it can provide necessary information
5. Minimize trauma to affected areas during scope insertion

Common Pitfalls to Avoid

1. Don't assume the rash is "just shingles": Screen for visceral involvement by asking about constipation, abdominal distention, or urinary retention 2, 4

2. Don't proceed without antiviral coverage: If the procedure is truly urgent, ensure the patient is on appropriate antiviral therapy

3. Don't ignore dermatome distribution: Herpes zoster affecting T10-L2 dermatomes has higher risk of affecting bowel innervation 2

4. Don't confuse post-procedure complications: Document the presence and extent of herpes zoster before the procedure to distinguish procedure-related complications from zoster-induced visceral neuropathy

Practical Management

For most clinical scenarios, the safest approach is to treat the herpes zoster first, then perform colonoscopy 2-4 weeks later when:

• Vesicles have crusted over
• Acute pain has resolved
• Risk of viral dissemination is minimal
• Patient can tolerate positioning and instrumentation comfortably

This approach avoids unnecessary surgical interventions that might result from misdiagnosing zoster-induced pseudo-obstruction as a procedural complication 2, 3.